MyFinsight
Home
Blog
About
Contact
Download
Download image
Net decrease in
cash, cash...
-$24,029K
Accounts receivable
-$18,000K
Share-based compensation
expense
$4,113K
Non-cash lease expense
$97K
Depreciation expense
$64K
Other assets
-$57K
Net cash used in
operating activities
-$8,937K
Net cash used in
investing activities
-$8,147K
Net cash used in
financing activities
-$6,945K
Canceled cashflow
$22,331K
Net loss
-$23,283K
Purchase of research and
development license
$8,000K
Purchases of property and
equipment
$147K
Payment of deferred
offering costs
$6,945K
Accrued expenses and
other current...
-$3,456K
Accounts
payable-Nonrelated Party
-$2,312K
Deferred revenue
-$1,039K
Prepaid expenses and
other current assets
$937K
Related party accounts
payable and other...
-$140K
Operating lease liability
-$101K
Back
Back
Cash Flow
CRESCENT BIOPHARMA, INC. (CBIO)
CRESCENT BIOPHARMA, INC. (CBIO)
source: myfinsight.com